Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip

Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip

This is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection.

This is a two-arm, randomized, open label, monocenter, controlled study to evaluate the safety and efficacy of Viusid plus Asbrip in patients with mild and moderate symptoms of respiratory illness caused by Coronavirus 2019 infection.

A total of 80 subjects will be randomized 2:1 in this study. 50 patients will be assigned to receive daily oral doses of 4,5 g of Viusid every 12 hours and 10 ml of Asbrip every 12 hours and standard care with antivirals or not. Other 30 patients will be assigned to receive only standard care.

Treatment duration: 21 days

Objective of the study: to increase the effectiveness of therapy for patients with Covid-19 using food supplements Viusid and Asbrip.

Research objectives:

1. To assess the clinical symptoms of Covid-19 in patients on the background of combination therapy with the inclusion of food supplements Viusid + Asbrip.
2. To investigate the dynamics of indicators of laboratory diagnostics against the background of complex therapy with the inclusion of food additives Viusid + Asbrip in the complex treatment of Covid -19.
3. To study the dynamics of indicators of instrumental methods of treatment.
4. To develop an algorithm for the management of patients with coronavirus infection in order to increase the effectiveness of therapy and rehabilitation of patients with this pathology.

The eligibility criteria for inclusion in the study were as follows:

• Male and female hospitalized patients who have signed an informed consent.
• Aged between 18-85 years old.
• RT-PCR confirmed COVID-19.
• Fever (over 37.2 Celsius degrees).
• CT scan percentage area of lung involvement with ground-glass opacities < 50 %.
• Respiratory rate < 20-30 /min
• SpO2 ≥ 95%.

The exclusion criteria were as follows:

• Oxygen support (ventilation and non-invasive)
• Uncompensated or exacerbated concomitant diseases or conditions that may complicate or make the patient's participation in the study impossible, or make it difficult to explain clinical findings.
• Any known intolerability to any of the study regimens' components.
• Patient's family or official relations with a member of staff of the clinical site.
• Patient's failure to assess his/her physical and/or emotional condition.
• Patient's failure to comply with the study requirements.
• Patient's refusal to participate in the study.
• Pregnancy or breastfeeding.